Economic Burden of Alzheimer's Disease and Dementia Care

The economic burden of Alzheimer’s disease and related dementias encompasses both direct expenditures for medical and social services and indirect costs incurred by families and caregivers. Direct costs include diagnostic investigations, pharmaceutical treatments, outpatient and inpatient care, long-term residential services and formal social support. Indirect costs arise primarily from unpaid informal care provided by family members, lost income and reduced workforce participation. Globally, total annual costs have been estimated in the order of hundreds of billions of US dollars, with projections indicating a doubling by mid-century driven by demographic ageing and rising prevalence. High-income countries continue to bear the largest share of expenditure, yet low- and middle-income regions face steep increases in both formal care costs and the hidden toll of informal care. Disease severity is a key cost driver: mild cases incur relatively modest care costs, which escalate two- to three-fold at moderate and severe stages. Social care and informal support together often exceed healthcare sector spending, underscoring the importance of integrated policy responses. The financial impact extends beyond health budgets to fiscal pressures on social services, lost productivity and household impoverishment, highlighting the urgent need for cost-effective interventions, risk-reduction strategies and equitable financing mechanisms worldwide.

Research from Nature Portfolio

Recent studies have applied detailed micro-costing methodologies to quantify provider expenditures in diverse healthcare settings. One multicentre observational analysis in a Southeast Asian tertiary hospital network used a bottom-up micro-costing framework to estimate annual per-patient direct healthcare costs of Alzheimer’s disease. It found an average cost of USD 572 per patient per year, with laboratory investigations accounting for 37 % of total spend, followed by clinic visits (32 %) and medications (25 %). Costs rose significantly with disease severity and patient age, underscoring the need for stage-specific resource planning. Such granular cost data support evidence-based health policy design and help identify key sectors for targeted efficiency improvements.

Economic Burden of Alzheimer's Disease and Dementia Care publication trend

The graph below shows the total number of articles in economic burden of alzheimer's disease and dementia care across all publications each year (not limited to Nature Index journals).

Technical terms

Direct costs: Expenditures on healthcare services, residential care, pharmaceuticals and formal social support.

Indirect costs: Economic value of unpaid informal care, productivity losses and income foregone by patients or caregivers.

Micro-costing approach: Bottom-up method that quantifies unit costs of individual service components to calculate total expenditure.

Prevalence-based cost-of-illness study: Analysis that estimates the economic burden by multiplying disease prevalence by per-patient cost.

Societal perspective: Analytical viewpoint that includes all costs regardless of payer, encompassing healthcare systems, social services and households.

References

1. Direct healthcare expenditure on Alzheimer’s disease from healthcare providers’ perspective in Malaysia: a micro-costing approach. Scientific Reports (2024).
2. Nonpharmacological intervention therapies for dementia: potential break-even intervention price and savings for selected risk factors in the European healthcare system. BMC Public Health (2024).
3. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimer's & Dementia (2016).
4. The costs of dementia in England. International Journal of Geriatric Psychiatry (2019).